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Objectives. To assess the capability of the visionmonitor unitMonpack One of detecting visual function alterations in patients with
multiple sclerosis (MS) and to evaluate the correlation between structural retinal parameters and functional measurements
obtained with this device.Methods. Forty-eight patients with MS and 46 healthy controls were included in a cross-sectional study.
All participants underwent a complete functional evaluation of the visual pathway, which included low-contrast visual acuity
(LCVA), contrast sensitivity vision (CSV), automated perimetry, multifocal visual evoked potentials (mfVEPs), and pattern
electroretinogram (ERG). All tests were performed using the vision monitor unit Monpack One (Metrovision, France), a
multifunction stimulator device. Retinal structural measurements were obtained in all subjects using Triton swept source optical
coherence tomography (Topcon, Japan). Results. Patients with MS presented reduced low-contrast VA (p< 0.001) and reduced
CSV at medium (p � 0.001, p � 0.013) and low (p � 0.001, p � 0.002) spatial frequencies. All visual field parameters were found
to be altered in MS patients compared with controls (≤0.001). Patients with MS presented lower amplitude of the P100 waveform
of the mfVEP in areas corresponding to central (p< 0.001), inferonasal (p � 0.001), and inferotemporal (p � 0.003) retina. )e
pattern ERG did not show significant differences. Significant correlations were observed between structural retinal measurements
and functional parameters, especially between the inner macular areas and measurements corresponding to contrast sensitivity
and perimetry indexes. Conclusions. Patients withMS present visual dysfunction detectable with the visionmonitor unit Monpack
One. )is device may be a fast and useful tool to provide a full evaluation of axonal damage in patients with multiple sclerosis.
1. Introduction
Multiple sclerosis (MS) is a multifocal central nervous system
disorder characterized by inflammatory demyelinating lesions
affecting white and gray matter. Even without a history of
optic neuritis (ON), optic nerve atrophy and thinning of the
peripapillary retinal nerve fiber layer are two typical findings
of patients suffering from MS [1].
Axonal loss is considered to be the main cause of
progressive disability in MS [1–3], and neuronal loss is
increasingly recognized as a biomarker that correlates with
disability in these patients [4–7]. MS is often associated with
involvement of the visual pathway that can lead to clinically
evident manifestations (such as ON and diplopia) and more
frequently, to subclinical alterations. Decreased contrast
sensitivity and color vision deficiencies have been widely
observed in MS [8–10] and have been correlated with poorer
performances in everyday tasks, such as driving and reading.
Previous research on functional evaluation of the visual
pathway demonstrated altered responses in MS. Visual
evoked potentials (VEPs) and pattern electroretinogram
(ERG) show frequent abnormalities in these patients [11–
13]. Asymptomatic visual field disturbances seem to be
present also in MS patients without a previous episode of
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optic neuritis [14]. Recent studies have correlated alterations
in functional responses with structural changes in the retina
of MS patients [10, 11].
In this study, we evaluated the visual pathway of MS
patients using the vision monitor unit Monpack One, a
multifunction stimulator device which integrates different
functional, electrophysiological, and psychophysical tests for
the complete evaluation of visual function parameters. )e
main objective of this study was to assess the capability of
this device of detecting visual function abnormalities
through different tests (visual acuity, contrast sensitivity
vision, perimetry, visual evoked potentials, and pattern
electroretinogram) in patients with MS and to analyze the
correlation between the functional measurements obtained
and retinal structural parameters measured with swept
source optical coherence tomography (SS-OCT).
2. Methods
Patients with definite relapsing-remitting (RR) MS were
included in this observational cross-sectional study. A total
of 48 eyes of 48 patients and 46 eyes of 46 healthy individuals
were evaluated. All procedures adhered to the tenets of the
Declaration of Helsinki, and all participants provided
written informed consent to participate in the study.
)e diagnosis of MS was based on the McDonald criteria
and confirmed by a neurologist [15]. Relatedmedical records
were carefully evaluated, and information about Expanded
Disability Status Scale (EDSS) scores, disease duration and
subtype, and modifying disease treatments and prior epi-
sodes of ON was recorded. Only patients with RR MS were
included in our study. Patients with a visual acuity <0.1
(using Snellen scale), intraocular pressure >20mmHg, re-
fractive errors >5 diopters (D) of equivalent spherical or 3D
of astigmatism, active MS outbreaks (of any neurologic
deficit), and/or history of a previous episode of ON were
excluded from our study.)e reason to exclude patients with
a prior ON episode was that visual function loss secondary to
ON is widely demonstrated, but the main purpose of this
study is to check if neuronal damage secondary to MS itself
(i.e., chronic neurodegeneration) causes subclinical visual
affectation. )e diagnosis of ON was based on reports from
the patient and the treating neurologist and clinical findings
such as decrease in visual acuity, visual defects in the
perimetry, color vision loss, relative afferent pupillary defect,
and papillary pallor observed in the funduscopy.
All eyes underwent a complete neuro-ophthalmic
evaluation that included pupillary, anterior segment, and
funduscopic examination to detect any ocular pathology that
might affect visual function tests.
Visual function was evaluated with the vision monitor
unit Monpack One (Metrovision, France), a multifunction
stimulator device which integrates different functional,
electrophysiological, phychophysical, and oculomotor tests
for a complete evaluation of visual function parameters. )e
visionmonitor comprises a central liquid crystal display panel
with LED backlight and four peripheral panels illuminated
with LEDs. A light sensor placed anteriorly provides feedback
to the entire system allowing a constant luminance during the
test performance. In our study, visual acuity (VA), contrast
sensitivity vision (CSV), visual field, multifocal PEV, and
pattern ERG were registered and analyzed in all eyes.
Low-contrast VA was evaluated at a contrast level of
10%. )e percentage indicates the level of contrast; that is,
100% would represent black letters over white background,
and 10% represents medium gray letters over white back-
ground. Two different ETDRS charts were selected (one
chart for each eye) to avoid learning and memory bias.
Measurements were obtained under scotopic light condi-
tions, at a distance of 4meters in monocular vision using
best correction. Visual results were recorded and registered
as a VA result (expressed in logMar) as well as the number of
total read letters.
Static CSV was evaluated using a sinusoidal pattern
(grid) at different spatial frequencies: 0.5, 1, 2, 5, 10, and 20
cycles per degree. )reshold CSV was analyzed by pro-
gressive increase of 0.25 dB of contrast before the test
performance. For contrast sensitivity evaluation, the patient/
control pressed a push-button when the contrast grid was
first visible in each spatial frequency. Measurements were
obtained at 2meters of distance under scotopic light con-
ditions andmonocular vision. CSV results were registered as
a sensitive curve in dB (0 representing no contrast
sensitivity).
Visual field was assessed using the vision monitor Fast
Perimetry 30 protocol (Fast-30), which analyzes 94 points
over the central visual field. )e test was performed in
monocular vision using near distance correction. Fixation
was controlled through a central video camera. Quality
parameters (i.e., fixation and attention) were analyzed, and
tests with poor performances (>5/15 fixation losses and >5/
15 attention losses) were automatically rejected by the
program. Results were presented as a 2D and 3D sensitivity
map (in dB), a color probability score map, and a sensitivity
curve. )e average deficit (AD), corrected average deficit
(CAD), variance of deficits (VD), and temporal fluctuation
(TF) were recorded.
Electrophysiological evaluation included multifocal
VEPs and pattern ERG. Multifocal VEPs were assessed
using alternate checkboards with a central fixation point.
Electrical responses were recorded using four electrodes
attached to the subject scalp by subcutaneous needles
(inion: 4 cm above the inion, 1 cm above the inion, and
4 cm right/left of the inion). )e ground electrode was
placed in the subject’s vertex. VEPs were evaluated with the
MVEP35 procedure, which analyzes 35 zones for each eye.
)e test was performed at a 33 cm distance, under scotopic
conditions after 2minutes light adaptation, using near
distance correction in monocular vision. Fixation was
controlled through a central video camera. Results were
presented as analytic data, amplitude histogram, color map,
and 3D representation for 5 different retinal areas: central,
superonasal, superotemporal, inferonasal, and inferotem-
poral. Amplitude of P100 wave for each retinal area was
recorded and expressed in nV/deg2.
)e pattern ERG was evaluated using alternate check-
boards with a central fixation point. Electrical responses were
recorded using a total of 5 DTL (Dawson–Trick–Litzkow)
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electrodes: 2 electrodes (one for the right eye and one for the
left eye) draped horizontally across the cornea at the level of
the lower lid (prior topical anesthesia) and 2 reference
electrodes positioned at the outer canthus (right and left eye).
)e ground electrode was placed at Fpz. )e pattern ERG
uses a reversal stimulation pattern covering a field of
60 degrees with large patterns for 50minutes. )e test was
performed at a distance of 30 cm, under scotopic conditions
after 2minutes of light adaptation, using near distance cor-
rection in binocular vision. Results are expressed as a graphic
of the electrical response registered and as the analytic data of
the different spikes selected. Amplitude and latency of the
N35, P50, and N95 waves (spikes) were recorded.
Structural measurements of the retina were obtained
using the DRI Triton SS-OCTdevice (Topcon, Tokyo, Japan)
in all eyes. )e 3D wide protocol was used, which includes a
wide scanning range that focuses on both the macular
(ETDRS: Early Treatment Diabetic Retinopathy Study) and
the peripapillary (TSNIT: temporal-superior-nasal-inferior-
temporal) area. With the ETDRS scan, full retinal thickness
in nine macular areas (which include a central 1mm circle
representing the fovea, and inner and outer rings measuring
3mm and 6mm in diameter, respectively) was analyzed; the
TSNIT scan provides automated separate measurements of
different retinal layers: retinal nerve fiber layer (RNFL),
ganglion cell layer (GCL), retinal thickness, and the cho-
roidal plexus. )e TSNIT provides measurements of the 4
peripapillary quadrants (superior, nasal, inferior, and tem-
poral), 6 sectors (superonasal, superotemporal, nasal, tem-
poral, inferonasal, and inferotemporal), and 12 clock sectors.
Only measurements of the GCL in the 6 peripapillary sectors
were evaluated in this study. All scans were obtained by the
same experienced operator and were checked by an expe-
rienced rater for quality of the segmentation immediately
after acquisition. )e DRI Triton SS-OCTprovides a quality
scale in the image to indicate the signal strength. )e quality
score ranges from 0 (poor quality) to 100 (excellent quality).
Only images with a score >55 were analyzed in our study;
poor quality images were rejected and recaptured prior to
data analysis.
All data analyses were performed using SPSS software
version 20.0 (SPSS Inc., Chicago, IL). )e Kolmogorov–
Smirnov test was used to assess sample distribution. Dif-
ferences between evaluations of MS patients and healthy
subjects were compared using the Mann–Whitney U test, as
the sample did not correspond to a normal distribution
(Kolmogorov test: p< 0.05). Correlation between functional
and structural data of all subjects (patients and controls) was
assessed using Spearman’s rho test. Correlation between the
EDSS score and visual function parameters was also ana-
lyzed. Each eye was considered separately, and only one eye
from each patient was randomly selected for analysis.
3. Results
Forty-eight patients with MS and 46 healthy controls were
included in the study. )e mean age of the patients with MS
was 49.25 (SD� 12.98), and the mean age of the healthy
controls was 45.74 (SD� 10.52). )e female/male ratio was
4/1 in both groups. Age, sex, and intraocular pressure did
not differ significantly between healthy controls and patients
with MS (p � 0.154, 0.145, and 0.770, respectively).
3.1. Visual Function Analysis. All patients had been di-
agnosed with MS relapse-remitting subtype and were under
treatment with interferon (50%), glatiramer acetate (12.5%),
or fingolimod (8.3%). Only 29.2% of the patients were not
under any current treatment.)e mean EDSS score was 2.03
(SD� 0.54).
Patients with MS presented reduced low-contrast VA
(0.43± 0.50 in patients vs. 0.08± 0.27 in controls, p< 0.001)
and reduced number of read letters (31.90± 8.20 letters vs.
39.70± 5.58 letters, p< 0.001) compared with healthy con-
trols (see Table 1).
CSV was found to be reduced inMS patients in all spatial
frequencies. CSV at medium frequencies (2 cpd: 21.29± 2.95
in patients vs. 22.06± 2.12 in controls, p � 0.001; 5 cpd:
20.34± 1.68 vs. 21.91± 1.94, p � 0.013) and low frequencies
(1 cpd: 19.09± 1.55 vs. 20.50± 2.02, p � 0.001; 0.5 cpd:
15.98± 1.69 vs. 17.04± 2.03, p � 0.002) was significantly
reduced in patients compared with controls (see Table 1).
All visual field parameters were found to be altered inMS
patients compared with controls. )e AD (p< 0.001), the
CAD (p< 0.001), the VD (p< 0.001), and the TF (p � 0.001)
were significantly reduced in patients compared with healthy
subjects (see Table 1).
Patients with MS presented lower amplitude of the P100
waveform in the multifocal VEP. Significant differences be-
tween patients and controls were observed in the areas
corresponding to central (798.80± 585.58 nV/deg2 in patients
vs. 1556.81± 1120.97 nV/deg2 in controls, p< 0.001), infer-
onasal (523.90± 262.71 nV/deg2 vs. 798.50± 390.14 nV/deg2,
p � 0.001), and inferotemporal (677.55± 730.19 nV/deg2 vs.
830.40± 380.09 nV/deg2, p � 0.003) retina (see Table 2).
Patients with MS also presented delayed latency in the N35,
P50, and N95 waveforms of the pattern ERG. However,
significant differences between patients and controls were not
found in any of the pattern ERG responses (see Table 2).
Reports from CSV andmfVEPs as provided byMonpack
One are seen in Figure 1.
3.2. Structural Evaluation. Patients presented significantly
reducedmacular retinal thickness (p< 0.001) in all evaluated
ETDRS areas and reduced peripapillary GCL thickness
(p< 0.001) in all 6 sectors analyzed, compared to healthy
controls (see Supplementary Table available here).
3.3. Correlation Analysis. A significant correlation was ob-
served between macular parameters and functional mea-
surements obtained with the Monpack One device. )e
inner superior and inner inferior areas correlated most
strongly with contrast sensitivity parameters (the strongest
correlation was observed between inner superior and 5 cpd,
r� 0.36, p< 0.001). All inner sectors of the macular ETDRS
ring presented a positive correlation with the number of read
letters (superior: r� 0.37, p< 0.001; nasal: r� 0.21, p � 0.042;
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inferior: r � 0.27, p � 0.009; and temporal: r � 0.26,
p � 0.011) and an inverse association with all visual field
parameters (the strongest correlation was observed be-
tween inner superior and VD, r � 0.35, p � 0.001). Central
thickness correlated with the P100 amplitude of central
retina measured with the mfVEP (r� 0.31, p � 0.002). No
correlations were found between functional parameters
and the outer macular areas. Results are shown in Tables 3
and 4.
Peripapillary GCL thickness (total and the temporal
quadrant) correlated significantly with most functional
parameters analyzed with the Monpack One device. A
positive correlation was observed between total GCL
thickness and CSV at 1, 2, 5, and 10 cpd (the strongest
correlation at 10 cpd, r� 0.28, p � 0.007), and a negative
association was observed between total GCL thickness and
visual field parameters (the strongest correlation with CAD,
r� − 0.32, p � 0.002). A positive correlation between total
GCL and the VEP in central retina (r� 0.26, p � 0.012) was
observed. Temporal GCL thickness correlated with CSV at 2,
5, 10, and 20 cpd (the strongest at 10 cpd, r� 0.40, p< 0.001)
and all visual field parameters (the strongest association with
CAD, r� − 0.36, p> 0.001). Additionally, a significant re-
lationship was observed between GCL thickness and letter
read (total GCL: r� 0.35, p � 0.001, and temporal GCL:
r� 0.39, p< 0.001). Results are shown in Table 3.
No significant correlations were observed between ERG
and structural parameters.
)e amplitude of mfVEPs in the central retina was
inversely correlated with the EDSS score (r � − 0.443,
p � 0.002). No other significant associations between
functional parameters and the EDSS score were observed.
4. Discussion
In the present study, we evaluated visual function param-
eters of 48 MS patients and 46 healthy controls using the
vision monitor unit Monpack One, a multiple function
stimulator device which integrates different functional,
electrophysiological, and phychophysical tests for a
Table 2: Electrophysiological parameters (standard deviation) in patients with multiple sclerosis and healthy controls, as measured with the
Monpack One device.
Electrophysiological parameters MS patients Controls p
mfVEPs (nV/deg2)
Central 798.80 (585.58) 1556.81 (1120.9) <0.001
Superonasal 504.00 (278.84) 637.95 (675.843) 0.455
Superotemporal 533.31 (292.29) 579.58 (341.27) 0.610
Inferonasal 523.90 (262.71) 798.50 (390.14) 0.001
Inferotemporal 677.55 (730.19) 830.40 (380.09) 0.003
Pattern ERG
N35 latency (msec) 27.18 (29.31) 23.82 (5.34) 0.515
N35 amplitude (mV) − 0.70 (1.34) − 0.62 (2.45) 0.534
P50 latency (msec) 46.59 (10.05) 43.34 (15.17) 0.471
P50 amplitude (mV) 4.43 (4.79) 7.21 (11.32) 0.097
N95 latency (msec) 83.09 (21.06) 71.07 (25.97) 0.070
N95 amplitude (mV) − 3.27 (5.38) − 4.79 (6.30) 0.184
Bold letters indicate statistical significance (p< 0.05). Abbreviations: MS, multiple sclerosis; mfVEPs, multifocal visual evoked potentials; ERG,
electroretinogram.
Table 1: Visual acuity, contrast sensitivity vision, and visual field parameters (standard deviation) in patients with multiple sclerosis and
healthy controls, as measured with the Monpack One device.
Functional parameters MS patients Controls p
Contrast vision
VA ETDRS 10% 0.43 (0.50) 0.08 (0.27) <0.001
Read letters 31.90 (8.20) 39.70 (5.58) <0.001
CSV 0.5 cpd 15.98 (1.69) 17.04 (2.03) 0.002
CSV 1 cpd 19.09 (1.55) 20.50 (2.02) 0.001
CSV 2 cpd 21.29 (2.95) 22.06 (2.12) 0.001
CSV 5 cpd 20.34 (1.68) 21.91 (1.94) 0.013
CSV 10 cpd 19.35 (2.60) 21.83 (2.84) 0.088
CSV 20 cpd 11.73 (4.31) 15.17 (3.21) 0.101
Visual field parameters
Avg. deficit 0.14 (0.35) 1.64 (2.87) <0.001
Corrected avg. deficit 0.20 (0.46) 1.57 (2.49) <0.001
Variance of deficits 4.05 (6.03) 14.65 (16.52) <0.001
Temporal fluctuation 0.98 (0.45) 1.73 (1.34) <0.001
Bold letters indicate statistical significance (p< 0.05). Abbreviations: MS, multiple sclerosis; VA, visual acuity; CSV, contrast sensitivity vision; cpd, cycles per
degree; avg., average.
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complete evaluation of visual function. To the best of our
knowledge, this is the first study featuring visual function
tests with Monpack One in patients with a neurodegener-
ative disease. Our patients presented lower VA, decreased
CSV affecting medium and lower frequencies, increased
defects in the visual field, and reduced amplitude in the P100
component of the multifocal VEP affecting the central and
inferior sectors of the retina. All these altered parameters
were observed using one single device, the vision monitor
unit Monpack One.
Visual dysfunction was previously reported in MS pa-
tients and may occur in up to 80% of cases during the course
of the disease [16]. Contrast sensitivity provides more
complete information about visual function than visual
acuity tests. Measures of low-contrast vision and CSV were
sensitive to visual impairment, even in patients with VA of
20/20 or better (measured with a Snellen chart), and have
been correlated with poorer performances in everyday tasks
[8, 17–20]. Our patients presented reduced CSV in low and
midspatial frequencies and low-contrast VA compared with
healthy controls, which is consistent to previous research
involving classic visual function tests [11, 21, 22] and tests
performed with other video processors [23, 24]. However,
high spatial frequencies were not significantly affected in our
patients, contrary to previous findings [11, 24]. More studies
including a larger sample size would be needed to establish
whether the Monpack One device detects significant dif-
ferences in CSV at high frequencies in MS.
Patients suffering from MS present visual field defects
compared with healthy controls, according to previous
Table 3: Correlation between visual function parameters obtained with the Monpack one device and structural parameters (macular and










r p r p r p r p
VA 10% 0.17 0.96 0.78 0.455 0.18 0.079 0.26 0.010
Letter read 0.37 <0.001 0.27 0.009 0.35 0.001 0.39 <0.001
CSV 0.5 0.18 0.083 0.09 0.370 0.15 0.131 0.20 0.053
CSV 1 0.27 0.007 0.18 0.069 0.23 0.023 0.20 0.048
CSV 2 0.34 0.001 0.25 0.013 0.23 0.024 0.25 0.016
CSV 5 0.36 <0.001 0.25 0.016 0.27 0.008 0.33 0.001
CSV 10 0.33 0.001 0.30 0.003 0.28 0.007 0.39 <0.001
CSV 20 0.25 0.014 0.26 0.011 0.13 0.135 0.25 0.013
Avg. deficit − 0.27 0.008 − 0.22 0.034 − 0.27 0.008 − 0.34 0.001
Corrected avg. deficit − 0.30 0.003 − 0.26 0.011 − 0.32 0.002 − 0.36 <0.001
Variance of deficits − 0.35 0.001 − 0.29 0.004 − 0.25 0.017 − 0.28 0.005
Temporal fluctuation − 0.30 0.003 − 0.24 0.019 − o.26 0.011 − 0.27 0.008
Bold letters indicate a significant correlation. Abbreviations: VA, visual acuity; CSV, contrast sensitivity vision; avg., average; GCL, ganglion cell layer.
Table 4: Correlation between visual field parameters obtained with the Monpack One device and macular measurements obtained with
Triton optical coherence tomography.
Visual function parameters
Central Inner superior Inner nasal Inner inferior Inner temporal
r p r p r p r p r p
Avg. deficit − 0.28 0.007 − 0.27 0.008 − 0.23 0.025 − 0.22 0.034 − 0.32 0.002
Corrected avg. deficit − 0.25 0.016 − 0.30 0.003 − 0.23 0.024 − 0.26 0.011 − 0.30 0.003
Variance of deficits − 0.25 0.017 − 0.35 0.001 − 0.25 0.014 − 0.29 0.004 − 0.33 0.001
Temporal fluctuation − 0.13 0.194 − 0.30 0.003 − 0.22 0.028 − 0.24 0.019 − 0.26 0.010
Bold letters indicate a significance <0.05. Abbreviations: avg., average.
(a) (b) (c)
Figure 1: (a)Monpack Onemonitor. (b) Displayed report of the contrast sensitivity vision test in one of our controls. (c) Displayed report of
multifocal visual evoked potentials in one of our controls.
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published research [25, 26]. However, other studies suggested
different results [27, 28]. Despite the fact that visual field
defects are more frequently reported in patients with MS and
previous history of ON [29], asymptomatic visual field dis-
turbances seem to be present also in patients without a
previous episode of ON [14].
Our patients presented significant alterations in all visual
field parameters compared with healthy controls, which are
consistent with results provided by Pueyo et al. and Castro
et al. Since none of our patients had a previous history of
ON, our results also agree with results provided by Chorazy
et al. and strengthen the evidence of visual field abnor-
malities in non-ON MS patients.
Electrophysiological responses of the visual pathway are
also altered in patients with MS [11, 30, 31]. According to
previous published studies, MS patients present increased
latency and decreased amplitude in the P100 waveform of
the pattern VEP [11, 27, 32, 33]. )e pattern VEP provides
information for a complete study of the visual pathway, from
the optic nerve to the visual cortex. )e pattern VEP has
been shown to be more sensitive than perimetry, contrast
sensitivity, and retinal structural defects at detecting hidden
visual loss in patients with MS with 20/20 vision and without
history of optic neuritis [30, 34]. However, the pattern VEP
is dominated by macular responses, thus other focal defects
may not be detected. )e multifocal VEP captures a sig-
nificantly larger area of the visual field than the pattern VEP
and can provide information of the global optical path,
topographic assessment of amplitude and latency, and thus
detects focal and peripheral defects [35]. Recent studies have
shown the sensitivity of the technique in identifying mul-
tifocal VEP defects after recovery from an episode of ON
[36] and also in patients suffering from MS (with and
without history of ON) [37]. Our patients presented de-
creased amplitude of P100 waveform in the multifocal VEP
(which represents neurodegeneration), especially those
corresponding to central, inferonasal, and inferotemporal
retina. Focal defects are not usually reported when per-
forming pattern VEPs [11].
)e pattern ERG is considered to be the most useful
neurophysiologic technology for detecting abnormalities in
the visual pathway caused by neurodegenerative diseases
[38]. Although the exact origin of the pattern ERG is not
clear, it seems to be generated by the inner layers of the
central retina (ganglion cells and their axons) [11], so it
reflects a more specific involvement of the retinal nerve fiber
layer anomalies than the alterations detected by PEV.
Previous research demonstrated increased latency of the
N95 waveform of the pattern ERG in patients with MS and
an increased P50/N95 ratio [11]. In the present study, MS
patients presented increased latencies of the N95 waveform
which is consistent with previous reports. However, this
difference between patients and controls was not found to be
significant, probably due to the small sample size of our
study.
Structural changes in the retina of patients with MS have
been widely studied. Optic nerve atrophy and thinning of the
peripapillary retinal nerve fiber layer are two typical findings
of patients with MS. Hitherto, studies using spectral-domain
OCT have revealed that the retina in non-ON eyes shows
peripapillary thinning compared to healthy controls [39, 40].
)e most recent milestone in the development of retina and
choroid visualization strategies is swept source OCT (SS-
OCT), with a scan speed of 100,000 A-scans/sec, which
provides more accurate three-dimensional images of the
retina and the choroid than previous spectral-domain de-
vices [41]. In our study, we used Triton SS-OCT to evaluate
the retina of patients withMS. Furthermore, we analyzed the
correlation between functional measurements obtained with
the Monpack One monitor and structural data measured
with Triton OCT. )e correlation between functional
changes in patients with MS [10] and other neurodegen-
erative diseases [42] and retinal structural measurements has
been previously evaluated using spectral-domain OCT de-
vices. To the best of our knowledge, this is the first study
assessing the correlation between visual function parameters
obtained with a multifunction simulator device and SS-OCT
technology. Our analysis revealed that contrast sensitivity
parameters and visual field data correlated most significantly
with macular and peripapillary measurements. However, the
strength of the association was limited. Correlations between
functional and structural retinal parameters are seldom
strong or perfect, since changes in structural parameters are
not happening at the same time as functional changes.)is is
frequently observed in glaucoma and also in neurodegen-
erative diseases such as MS, and Parkinson electrophysio-
logical tests performed with the Monpack One device
demonstrated barely no association with obtained structural
data, opposite to previous studies where significant asso-
ciation between structural changes and electroretinogram/
multifocal visual evoked potentials was observed [43, 44].
Nonparametric tests (as the one used in our calculations)
tests are more demanding to accept statistical differences;
this also might explain why we did not find more association
between parameters. Additionally, devices used in previous
studies (to obtain both structural and functional data) differ
from what was used in our present study; we believe results
might not be entirely comparable. However, our results
suggest that the correlation between functional data ob-
tained with the multifunction simulator device and struc-
tural retinal measurements may only be applicable to CSV
tests and perimetry data. In addition, there were no ob-
servable differences between MS patients and controls in the
ERG measurements (opposite to previous reported data).
Taken altogether, these results might suggest that the ability
of the ERG function of the Monpack One monitor should be
improved. However, more studies using the multifunction
simulator device Monpack One are needed to corroborate
our findings.
)e main goal of this study was to analyze the capability
of the vision monitor unit Monpack One of detecting visual
dysfunction in MS. Low-contrast VA, CSV, visual field
parameters, and multifocal VEPs were significantly altered
in our patients, and these results agree with previous
published research. Additionally, since none of our patients
presented any previous episode of optic neuritis, which
causes inflammation and retrograde retinal cells alteration,
we are certain that results in our patients were associated
6 Journal of Ophthalmology
with disease itself and not with previous inflammatory
episodes of the optic nerve. Moreover, similar alterations in
visual function tests in these patients have been associated
with axonal loss secondary to MS [10, 11].
In conclusion, patients with MS and without ON ante-
cedent present visual dysfunction detectable with the vision
monitor unit Monpack One. Measurements obtained with
this device correlate with structural retinal data obtained with
SS-OCT technology. Monpack One may be a fast and useful
tool to provide a complete evaluation of axonal damage in
patients with MS, although some of the electrophysiological
tests might require further improvement.
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